Chicago CMO opens potent small molecule site

By Fiona BARRY contact

- Last updated on GMT

Regis Technologies will offer an HPAPI service
Regis Technologies will offer an HPAPI service

Related tags: Pharmacology, Manufacturing

Contract manufacturing organisation Regis Technologies has added an HPAPI (highly potent active pharmaceutical ingredient) service.

The Chicago-based company will manufacture materials for small molecule oncology drugs, and linkers and payloads for antibody drug conjugates. A Potent Compound Suite will allow cGMP manufacturing up to 1kg per batch.

HPAPI production requires specialised facilities to minimise contamination risks. The site is equipped withisolators, laminar flow hoods and local exhaust ventilation.

The facility has a containment performance target (CPT) set to 50 ng/m3, based on the occupational exposure limits (OELs) of the specific APIs to be manufactured there.

Regis already operates a 36,000 sq ft cGMP facility in Morton Grove, Illinois. As well as cGMP API manufacturing, it performs chiral separations, scale-up, and commercial manufacturing. ​ 

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Case Study: SmartSignals eConsent

Case Study: SmartSignals eConsent

Signant Health | 15-Feb-2022 | Case Study

Signant’s eConsent solution helped a sponsor manage the consenting process complexities in their pediatric attention deficit hyperactivity disorder (ADHD)...

Related suppliers

Follow us


View more